[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epilepsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epilepsy":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,227,0,25,[9,47,78,108,132,169,192,218,240,266,284,315,332,360,382,407,431,448,472,496,520,542,577,597,623],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100249911","phase-1-investigation-of-blood-brain-barrier-breakdown-using-manganese-magnetic-resonance-imaging-in-drug-resistant-epilepsy-100249911",false,"NCT02531880","Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy","* INCLUSION CRITERIA:\n* Age 18-60.\n* Able to give written informed consent directly.\n* Drug resistant epilepsy participants will be defined as having clinically documented seizures with consistent EEG evidence as defined by the 1981 International Classification of Epileptic Seizures, refractory to standard anti-seizure treatment for at least one year prior to enrolling in this study and with an average of at least one seizure per month. This criterion will be established by preliminary screening NINDS Epilepsy Service under protocol 18-N-0066. Seizure focus localization will be determined by standard clinical, neurophysiologic, and imaging studies. Prior or concurrent enrollment in 18-N-0066 is required.\n\nEXCLUSION CRITERIA:\n\nGeneral exclusions:\n\n* Patients with epilepsy who are not surgical candidates\n* Significant structural brain abnormality such as a brain tumor, stroke, brain damage from head trauma or blood vessel abnormalities, on the baseline MRI scan.\n* Positive test for HIV\n* Pregnancy or breast-feeding\n* Claustrophobia to a degree that the subject would feel uncomfortable in the MRI machine.\n* Cannot lie on their back for at least two hours.\n* Risk for MRI scan, (e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that cannot be removed, or history of being a welder or metal worker due to small metal fragments in the eye)\n* Unwilling to allow sharing and\u002For use in future studies of coded data that are collected for this study\n\nMEMRI component specific exclusions (applicable only to patients participating in this arm of the study):\n\n* History of post-ictal psychosis or post-ictal aggression\n* Planning to get pregnant in the next 2 months\n* History of clinically significant liver or kidney disease that could potentially increase the risk of CNS damage due to manganese exposure\n* A history of drug or alcohol abuse\u002Fdependence (subjects scoring 8 or higher on the AUDIT scale)\n* Screening lab abnormalities demonstrating values more than 2 times the upper limit of normal for AST, ALT, bilirubin, alkaline phosphatase, BUN, creatinine\n* Previous presumed occupational exposure to manganese (i.e., having worked in a mine, foundry, smelter, dry cell battery manufacturing facility, or agriculture)\n* Allergy to manganese\n* On-going treatment with calcium-channel blocker\n* Iron-deficiency anemia\n* Personal history of Parkinson s Disease or Parkinsonism or presence of this disease in a 1st degree relative\n\nGadolinium enhanced MRI component specific exclusions (applicable only to patients participating in this arm of the study):\n\n* Estimated GFR \\\u003C60, tested within 1 week of scan\n* Allergy to gadolinium\n\nOf note, patients who are ineligible for one arm of the study may still be eligible for and participate in the other arm of the study.","ALL","18 Years","60 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\n\\- The blood-brain barrier separates the brain from the rest of the body. Epilepsy is a neurological disease that causes seizures. It can affect this barrier. Researchers think a contrast agent called mangafodipir might be better able to show areas of the brain that epilepsy affects.\n\nObjective:\n\n\\- To see if mangafodipir is well tolerated and safe. To see if magnetic resonance imaging (MRI) using either mangafodipir or gadolinium can show areas of blood-brain barrier breakdown in people with epilepsy.\n\nEligibility:\n\n* People ages 18-60 who:\n* Have epilepsy not controlled by drugs\n* Prior or concurrent enrollment in 18-N-0066 is required\n\nDesign:\n\n* Participants will be screened with:\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Participants will have up to 6 visits in 1-3 months. One visit is an inpatient stay lasting 2-10 days. Visits may include:\n* Video-EEG monitoring for participants with epilepsy\n* An IV catheter put in place: a needle guides a thin plastic tube into an arm vein.\n* Getting mangafodipir through the IV.\n* Getting gadolinium through the IV.\n* Up to 6 MRI scans over a 10-day period: a magnetic field and radio waves take pictures of the brain. Participants lie on a table that slides into a metal cylinder. They are in the cylinder for 45-90 minutes, lying still for up to 10 minutes at a time. The scanner makes loud knocking sounds. Participants will get earplugs.\n* A final MRI at least 2 weeks after receiving mangafodipir....",[27],"Epilepsy",[29,30,31,32,33],"MRI","Manganese Enhanced MRI","Seizure Disorder","Seizures","Epileptic Focus","RECRUITING","2026-08-14",{"date":37,"type":38},"2026-08-17","ACTUAL",{"date":40,"type":38},"2024-11-19",{"date":42,"type":21},"2030-07-01",{"name":44,"class":45},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100651953","phase-2-electrophysiologic-mechanisms-of-ketamine-antidepressant-response-100651953","NCT07768618","Electrophysiologic Mechanisms of Ketamine Antidepressant Response","Electrophysiologic Dynamics of Depression and Antidepressant Response in Epilepsy","Ketamine-sEEG","Inclusion Criteria:\n\n* Admitted to the Emory EMU for clinically indicated sEEG monitoring for epilepsy.\n* At least mild depressive symptoms at baseline, defined as MADRS ≥7 or BDI-II ≥14.\n* Electrode coverage that includes midline regions sufficient for enrollment and analyses.\n* Ability to provide informed consent and to complete bedside tasks\u002Fquestionnaires in English.\n* Expected to remain under inpatient monitoring through the planned \\~24-hour post-infusion follow-up unless clinical needs dictate otherwise.\n\nExclusion Criteria:\n\n* Documented IQ \\\u003C70, intellectual disability, severe cognitive impairment, delirium, severe aphasia, or other condition that prevents valid consent or task participation.\n* Current or past schizophrenia-spectrum disorder or other psychotic disorder.\n* Current manic\u002Fhypomanic episode or bipolar-spectrum illness judged by study psychiatrist\u002Finvestigator to increase risk or confound interpretation.\n* Active alcohol or substance abuse\u002Fdependence within the past 3 months.\n* Imminent suicide risk or active suicidal intent requiring urgent intervention as determined by clinical assessment. Passive ideation without imminent intent may be considered on a case-by-case basis with psychiatric approval and enhanced monitoring.\n* Contraindication to subanesthetic ketamine, including uncontrolled hypertension, unstable cardiovascular disease, aneurysm\u002Fvascular malformation or similar condition conferring unacceptable risk, pregnancy, breastfeeding, or other clinically significant medical instability.\n* Clinical team determination that ketamine administration or study timing would interfere with epilepsy care or perioperative management.\n* Sedative or other medication exposure at a level that, in the judgment of the clinical team, precludes safe ketamine administration or reliable behavioral assessment (participant may be deferred rather than permanently excluded if the issue resolves).",{"count":56,"type":21},37,[58],"PHASE2","This study aims to identify electrophysiologic biomarkers associated with antidepressant response to ketamine in adults with epilepsy undergoing clinically indicated stereo-electroencephalography (sEEG) monitoring who have at least mild depressive symptoms.\n\nParticipants will receive a single subanesthetic intravenous ketamine infusion (0.5 mg\u002Fkg over 40 minutes) during their Epilepsy Monitoring Unit admission. Intracranial neural recordings and behavioral assessments will be collected before and approximately 24 hours after infusion to examine changes in neural circuits associated with rumination and anhedonia.",[27,61],"Depressive Symptoms",[63,27,64,65,66,67],"Depression","Ketamine","Stereo-electroencephalography","Antidepressant Response","Electrophysiologic Biomarker","NOT_YET_RECRUITING","2026-08-12",{"date":37,"type":38},{"date":72,"type":21},"2026-12",{"date":74,"type":21},"2031-12",{"name":76,"class":77},"Emory University","OTHER",{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100636299","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-focus-1-100636299","NCT07563881","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 1","Inclusion Criteria:\n\n1. Age 18 - 75\n2. BMI 18-45 kg\u002Fm2\n3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1\n4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis\n5. Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs\n6. Ability to keep accurate daily focal seizure records using an e-diary\n\nExclusion Criteria:\n\n1. Known hypersensitivity or prior exposure to RAP-219.\n2. Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur\n3. Anticipated need for surgery during the study period\n4. Medical history of any of the following:\n\n   1. generalized epilepsy\n   2. focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type\n   3. psychogenic nonepileptic seizure (PNES)\n   4. status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).\n   5. epilepsy surgery within 12 months prior to Visit 1 (Day -56).\n5. Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product","75 Years",{"count":88,"type":21},333,[90],"PHASE3","This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.",[93,27,94],"Focal Seizure","Focal Epilepsy",[96,97],"Focal Preserved Consciousness","Focal Impaired Consciousness",{"date":99,"type":38},"2026-08-13",{"date":101,"type":38},"2026-06-05",{"date":103,"type":21},"2029-09",{"name":105,"class":106},"Rapport Therapeutics Inc.","INDUSTRY",10,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100217448","noninvasive-pre-surgical-evaluation-of-patients-with-focal-epilepsy-and-establishment-of-a-normative-imaging-database-100217448","NCT02107989","Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database","* INCLUSION CRITERIA FOR PATIENTS:\n* Age 8 and older\n* Evaluated or under evaluation for epilepsy surgery under protocol 18-N-0066,11-N-0051 or 16-N-0041\n* Documentation of focal epilepsy based on MRI, EEG and\u002For ictal semiology\n* Ability to give informed consent, have or be able to assign a legally authorized representative able to give consent (for adults without consent capacity), or parent\u002Fguardian able to provide informed consent (for a child).\n\nINCLUSION CRITERIA FOR PATIENTS SOLELY CONTRIBUTING DATA:\n\n* Had epilepsy surgery with presurgical evaluation under 18-N-0066\n* Age 8 and up at the time of epilepsy surgery evaluation\n* Had a preoperative structural brain MRI of the type used in this protocol\n\nINCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\n* Age 8 and older\n* Ability to give informed consent or have a parent\u002Fguardian able to provide informed consent if a child.\n* Ability to cooperate with MRI scanning without anesthesia\n\nEXCLUSION CRITERIA FOR PATIENTS:\n\n* Contraindications to MRI or MEG studies (such as pacemakers, cochlear implants, shrapnel, permanent eyeliner)\n* Claustrophobia or anxiety disorders exacerbated by the MRI scanner\n* Pregnancy. All females of childbearing potential must have a negative pregnancy test prior to MRI scanning\n\nEXCLUSION CRITERIA FOR PATIENTS SOLELY CONTRIBUTING DATA:\n\n-Not able or willing to give consent or do not have an appropriate surrogate who can provide consent\n\nEXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\n* Contraindications to MRI or MEG studies (such as pacemakers, cochlear implants, shrapnel, permanent eyeliner)\n* Claustrophobia or anxiety disorders exacerbated by the MRI scanner\n* Significant medical conditions that may affect the central nervous system, such as psychiatric disorders (such as mood disorders, psychotic disorders, substance abuse or dependence), significant neurologic disorders (such as brain injury, neurodegenerative disorders, multiple sclerosis, stroke, movement disorders, epilepsy), or active systemic disease that may affect the central nervous system (such as uncontrolled hypertension, autoimmune disorders or other inflammatory disorders, neoplastic disease)\n* Use of centrally acting medications in the past 6 weeks, such as benzodiazepines, barbiturates, antidepressants, beta-blockers, and drugs for treating epilepsy or migraine\n* Pregnancy. All females of childbearing potential must have a negative pregnancy test prior to MRI scanning",true,"8 Years","120 Years",{"count":118,"type":21},700,"OBSERVATIONAL","Objectives:\n\nThe overall study objective is to compare the sensitivities and specificities of morphometric analysis techniques using structural MRI images based on pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy. To carry out these analyses, we aim to establish an age-stratified normative imaging database using healthy volunteers. Additional objectives are to identify abnormal networks in these patients using resting state fMRI\u002FEEG and MEG\u002FEEG, and to use language and memory fMRI tasks to examine the effects of epileptogenic zones and surgery on cognitive function and the networks associated with these functions.\n\nStudy population:\n\n300 adults and children (age 8 and older) with uncontrolled focal epilepsy, and 200 age-stratified healthy volunteers.\n\nDesign: A retrospective and prospective natural history study. Research procedures for patients in this study include neuropsychological testing and 1-4 MRI sessions during presurgical evaluation and an additional 1-3 MRI sessions and neuropsychological testing approximately 12 months post-operatively. Research testing (such as research neuropsychological tests or MRI scanning sequences) will be done during a visit for clinical testing whenever possible, likely reducing the number of required visits. Patients will also have optional MEG and 7T structural imaging. Data will also be obtained from patients who have already undergone epilepsy surgery if they had procedures as outlined in the protocol and are willing to share the data. Healthy volunteers will receive a subset of the pre-operative procedures for patients, requiring at least 3 visits. In order to ensure adequate data acquisition, subjects may be re-scanned up to three times for the portions of the study in which they participated, possibly requiring additional visits.\n\nOutcome measures:\n\nThe main outcomes will be establishment of normative values for morphometric analysis methods in age-stratified normal controls, and comparison of the sensitivity and specificity of these measures to pre- and postsurgical localization of the epileptogenic zone. Secondary outcome measures will include determination of the sensitivity and specificity of source localization using MEG\u002FEEG and resting state fMRI\u002FEEG, and to evaluate changes in activation during rest, as well as language and memory fMRI tasks in patients pre- and postsurgically, to examine the effects of epileptogenic zones and surgery on cognitive function and the networks underlying these functions.",[27],[27,29,123,124,125],"fMRI","MEG","Natural History",{"date":99,"type":38},{"date":128,"type":38},"2014-03-11",{"date":130,"type":21},"2028-03-30",{"name":44,"class":45},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":152,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":46},"100625026","lifus-for-neurological-disorders-100625026","NCT07417280","LIFUS For Neurological Disorders","Clinical Effects of Low-Intensity Focused Ultrasound Neuromodulation in Patients With Neurological and Psychiatric Disorders","Inclusion Criteria:\n\n* 18-85 years of age\n* Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder)\n* Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders\n\nExclusion Criteria:\n\n* History of stroke\n* Comorbid dementia\n* Scored below 22 on the Montreal Cognitive Assessment (MoCA)\n* Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)\n* Presence of metal implanted in body that is contraindicated in TMS\u002FMRI\n* Pregnancy\n* Major depression\u002Fpsychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study\n* Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol\n* Major systemic illness or infection","85 Years",{"count":141,"type":21},50,[143],"NA","Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.",[146,147,148,149,27,150,151],"Parkinson's Disease (PD)","Essential Tremor","Orthostatic Tremor","Dystonia","Substance Abuse Disorder","Deep Brain Stimulation",[153,147,148,149,27,150,151,154,155,156,157,158,159,160],"Parkinson's Disease","DBS","Substance Use Disorder","SUD","PD","LIFUS","Low-Intensity Focused Ultrasound","Neuromodulation","2026-08-11",{"date":99,"type":38},{"date":164,"type":38},"2025-12-02",{"date":166,"type":21},"2040-12-31",{"name":168,"class":77},"University Health Network, Toronto",{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":16,"minAge":115,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":4,"leadSponsor":191,"locationsCount":46},"100153739","surgery-as-a-treatment-for-medically-intractable-epilepsy-100153739","NCT01273129","Surgery as a Treatment for Medically Intractable Epilepsy","* INCLUSION CRITERIA:\n\nTo be eligible for entry into the study, candidates must:\n\n1\\. Be 8 years of age or older with drug resistant epilepsy or tumor related epilepsy.\n\nEXCLUSION CRITERIA:\n\nCandidates will be excluded if they:\n\n1\\. Are unable or unwilling to give informed consent, or have a parent able to provide informed consent if a minor, to the research procedures.","99 Years",{"count":177,"type":21},300,"Background:\n\n\\- Drug resistant epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures completely or almost completely in one-half to two-thirds of patients who qualify for surgery. The tests and surgery performed as part of this treatment are not experimental, but researchers are interested in using the data collected as part of routine standard epilepsy care to better understand epilepsy and its treatment.\n\nObjectives:\n\n\\- To use surgery as a treatment for drug resistant epilepsy in children and adults.\n\nEligibility:\n\n\\- Children and adults at least 8 years of age who have simple or complex partial seizures (seizures that come from one area of the brain) that have not responded to medication, and who are willing to have brain surgery to treat their medically intractable epilepsy.\n\nDesign:\n\n* Participants will be screened with a medical history, physical examination, and neurological examination. Imaging studies, including magnetic resonance imaging and computer-assisted tomography (CT), may also be conducted as part of the screening. Participants who do not need surgery or whose epilepsy cannot be treated surgically will follow up with a primary care physician or neurologist and will not need to return to the National Institutes of Health for this study.\n* Prior to the surgery, participants will have the following procedures to provide information on the correct surgical approach.\n* Video electroencephalography monitoring to measure brain activity during normal activities within a 24-hour period. Three to four 15-minute breaks are allowed within this period.\n* Electrodes placed directly in the brain or on the surface of the brain to measure brain activities and determine the part of the brain that is responsible for the seizures (seizure focus).\n* Participants will have a surgical procedure at the site of their seizure focus. Brain lesions, abnormal blood vessels, tumors, infections, or other areas of brain abnormality will be either removed or treated in a way that will stop or help prevent the spread of seizures without affecting irreplaceable brain functions, such as the ability to speak, understand, move, feel, or see.\n* Participants will return for outpatient visits and brain imaging studies 2 months, 1 year, and 2 years after surgery.",[27,180,181],"Epilepsy, Temporal Lobe","Partial Epilepsy",[183,184,27,185,186,125],"Neurosurgery","Childhood Epilepsy","Frontal Lobe Epilepsy","Temporal Lobe Epilepsy","2026-08-08",{"date":161,"type":38},{"date":190,"type":38},"2011-03-21",{"name":44,"class":45},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":46},"100612088","impact-of-epilepsy-on-the-brainstem-adenosine-pathway-and-its-relation-with-arousal-and-respiratory-reactivity-100612088","NCT07249034","Impact of Epilepsy on the Brainstem Adenosine Pathway and Its Relation With Arousal and Respiratory Reactivity","BRAVE","Inclusion Criteria:\n\n* For patients\n\n  1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study\n  2. Aged 18 to 55 years old\n  3. Diagnosis of focal epilepsy or of idiopathic generalized epilepsy, as defined by the International League Against Epilepsy\n  4. Diagnosis of refractory epilepsy, as defined by the International League Against Epilepsy as failure of adequate trials of two tolerated, appropriately chosen and used antiseizure drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom\n  5. Patients with ≥3 focal to bilateral tonic-clonic seizure (FBTCS) or generalized tonic-clonic seizure (GTCS) during the past 18 months\n  6. For women of childbearing potential, use highly effective contraception until the end of relevant systemic exposure (V2)\n* For healthy volunteers\n\n  1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study\n  2. Aged 18 to 55 years old\n  3. For women of childbearing potential, use highly effective contraception until the end of relevant systemic exposure (V2)\n\nExclusion Criteria:\n\n* For patients\n\n  1. Ongoing or chronic respiratory insufficiency defined as breathlessness Grade ≥ 2 using the modified Medical Research Council Dyspnea Scale and\u002For patient treated by a pneumologist for respiratory insufficiency\n  2. Cardiac insufficiency defined as symptoms Grade ≥ 2 using New York Heart Association Functional Classification and\u002For patient treated by a cardiologist for chronic heart failure\n  3. Ischaemic heart disease defined as history of myocardial ischemia and\u002For of typical angina confirmed by a cardiologist.\n  4. Obstructive sleep-apnea syndrome, defined as participant who had been diagnosed for Obstructive sleep apnoea by polysomnography, whether a dedicated therapy is ongoing or not\n  5. Ongoing treatment with selective serotonin reuptake inhibitor (Selective Serotonin Reuptake Inhibitors): Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors): Duloxetine, Milnacipran, Venlafaxine\n  6. Hypercapnic challenges contra-indication (History of stroke in the last 5 years, space-occupying lesion in the brain associated with brain oedema and\u002For mass effect on MRI\u002FCT scan)\n  7. MRI contra-indication (presence of metallic elements, claustrophobia)\n  8. Patient treated with vagal nerve stimulation or deep brain stimulation\n  9. Pregnant women, women in labor or breastfeeding women, based on declarations at V0\n  10. Patients suffering from a psychiatric disorder, regardless of its etiology, whose care is provided under compulsory measures\n  11. Persons deprived of their liberty by a judicial or administrative decision\n  12. Adults subject to a legal protection measure (guardianship, curatorship)\n  13. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme\n  14. Positive urine pregnancy test at V2, if applicable\n  15. Hypersensitivity to \\[18F\\]-CPFPX\n* For healthy volunteers\n\n  1. History of epilepsy\n  2. Ongoing or chronic respiratory insufficiency defined as breathlessness Grade ≥ 2 using the modified Medical Research Council Dyspnea Scale and\u002For patient treated by a pneumologist for respiratory insufficiency\n  3. Cardiac insufficiency defined as symptoms Grade ≥ 2 using New York Heart Association Functional Classification and\u002For patient treated by a cardiologist for chronic heart failure\n  4. Ischaemic heart disease defined as history of myocardial ischemia and\u002For of typical angina confirmed by a cardiologist.\n  5. Obstructive sleep-apnea syndrome, defined as participant who had been diagnosed for Obstructive sleep apnoea by polysomnography, whether a dedicated therapy is ongoing or not\n  6. Ongoing treatment with selective serotonin reuptake inhibitor : SSRIs (Selective Serotonin Reuptake Inhibitors) : Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) : Duloxetine, Milnacipran, Venlafaxine\n  7. Hypercapnic challenges contra-indication (History of stroke in the last 5 years, space-occupying lesion in the brain associated with brain oedema and\u002For mass effect on MRI\u002FCT scan)\n  8. MRI contra-indication (presence of metallic elements, claustrophobia)\n  9. Pregnant women, women in labor or breastfeeding women, based on declarations at V0\n  10. Patients suffering from a psychiatric disorder, regardless of its etiology, whose care is provided under compulsory measures\n  11. Persons deprived of their liberty by a judicial or administrative decision\n  12. Adults subject to a legal protection measure (guardianship, curatorship)\n  13. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme\n  14. Positive urine pregnancy test at V2, if applicable\n  15. Hypersensitivity to \\[18F\\]-CPFPX","55 Years",{"count":141,"type":21},[143],"Despite the continuous development of new antiseizure medications over the past 25 years, 30% of patients with epilepsy suffer from drug-resistant seizures and are at risk of epilepsy-related complications, like cognitive dysfunctions, sleep-disordered breathing or Sudden and Unexpected Death in Epilepsy (SUDEP). SUDEP typically occurs during sleep, after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting that interaction between respiratory dysfunction and sleep state may play a role in its pathophysiology.\n\nPost-mortem data in SUDEP patients showed alteration of neuronal populations involved in respiratory control in the medulla. Accordingly, pharmacologic strategies aimed at reducing the severity of postictal respiratory dysfunction has appeared as one of the most promising way to prevent SUDEP. However, no encouraging result has hitherto been reported.\n\nInterconnections between the complex network that regulates arousal and sleep and the respiratory network are numerous. They primarily include the relation between chemosensitive regulation and arousal system to ensure asphyxia-induced arousal (i.e. arousal to elevated CO2), especially through serotonin (5HT)-dependent connections in brain stem. The link between alterations of the brainstem networks involved in arousal regulation and respiratory dysfunction has not been characterized in patients with epilepsy yet.\n\nLike 5HT, adenosine is deeply implicated in the regulation of sleep and central respiratory control.\n\nSeizures transiently increase adenosine extracellular levels. Adenosine physiological effects in the brain are mediated through the activation of two types of Adenosine receptors (ARs), A1Rs and A2ARs. Extracellular adenosine promotes sleep via A1R-dependant inhibition of glutamatergic neurons in the basal forebrain, but also via A2AR-dependant activation of neurons in the nucleus accumbens. Respiration is also inhibited by A1R and A2AR. Most importantly, it has been shown that drug-resistant epilepsy is associated with long-term alterations of ARs cortical expression. However, whether or not a similar epilepsy-related plasticity of ARs occurs in the brainstem and may participate to chronic arousal and respiratory dysfunction in epilepsy has never been investigated.\n\nConsidering the tight interplay between central respiratory control, arousal regulation and brainstem adenosine, the main hypothesis of the BRAVE study is that epilepsy might result in alterations of the distribution of A1Rs in the brainstem structures involved in respiratory regulation and\u002For arousal control, especially in the brainstem structures involved in respiratory regulation under hypercapnic condition.\n\nThe study combines clinical respiratory characterization, morphological, functional and metabolic imaging, using the hybrid simultaneous 3T MRI-PET scanner (Siemens Biograph mMR) of the CERMEP. Combining PET with anatomical and functional MR imaging enables non-invasively in vivo mapping of receptor binding and functional neuronal assessment of a physiological task in the entire brain with high spatial resolution.\n\nInvestigators already performed fMRI study of respiratory centers, showing number of functional changes in brainstem regions participating to the central control of respiration, including reduced activation during breath-holding fMRI, in patients with epilepsy. The BRAVE study will use the same respiratory paradigm as the one used in this past study.\n\nPET imaging will be focused on A1R, using \\[18F\\]CPFPX, a selective A1R antagonist.",[27,204,205],"Drug-resistant Focal Epilepsy","Healthy Controls",[27,207,208,209,210],"adenosine pathway","respiratory reactivity","PET-MRI","[18F]CPFPX","2026-08-07",{"date":161,"type":38},{"date":211,"type":21},{"date":215,"type":21},"2028-10-07",{"name":217,"class":77},"Hospices Civils de Lyon",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":16,"minAge":225,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100587897","subcortical-arousal-in-perceptual-awareness-100587897","NCT06934356","Subcortical Arousal in Perceptual Awareness","Shared Subcortical Arousal Systems Across Perceptual Modalities","A. The following are the inclusion\u002Fexclusion criteria for healthy participants age 18 years and up (Aim 1 and 2):\n\nInclusion: (1) normal vision with or without the use of corrective lenses; (2) normal hearing not needing an assistive hearing device.\n\nExclusion: (1) past history of diagnosis of a psychiatric or neurologic disease; (2) current psychiatric or neurologic disease; (3) requires hard contact lenses or glasses to maintain normal vision (prevents accurate pupil and eye gaze measurements); (4) pregnant or nonremovable ferrous metal objects inside or on the body (prevents MRI).\n\nB. The following are the inclusion\u002Fexclusion criteria for epilepsy patients with thalamic electrodes age 13 years and up (Aim 3A):\n\nInclusion: (1) normal vision with or without the use of corrective lenses\n\nExclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves.\n\nC. The following are the inclusion\u002Fexclusion criteria for epilepsy patients with thalamic electrodes age 18 year and up (Aim 3B):\n\nInclusion: (1) normal vision with or without the use of corrective lenses; (2) A female subject must have a negative pregnancy test and if sexually active, must be using a reliable form of birth control for the duration of the trial, be surgically sterile, or be at least two years post-menopausal.\n\nExclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves; (3) Pregnancy.","13 Years",{"count":227,"type":21},202,[143],"The study consists of prospective enrollment of healthy participants and patients with epilepsy, as well as analysis of an existing data set. Healthy participants will be studied with fMRI, eye metrics and behavioral testing at Yale. Patients will be studied with intracranial thalamic and cortical recording and stimulation, eye metrics and behavioral testing.",[27],{"date":232,"type":38},"2026-08-10",{"date":234,"type":38},"2025-10-13",{"date":236,"type":21},"2030-12",{"name":238,"class":77},"Yale University",8,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":16,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100585113","acute-stimulation-and-modulation-of-stereotyped-high-frequency-oscillations-100585113","NCT06898138","Acute Stimulation and Modulation of Stereotyped High-Frequency Oscillations","Acute Stimulation for the Modulation of Epileptic Events With a Closed-Loop Brain Interchange System in Drug Resistant Epilepsy","Inclusion Criteria:\n\n* Patients with medically refractory epilepsy, who have been deemed appropriate candidates for intracranial EEG monitoring\n* Adult men and women (18≤ age \\\u003C70 years)\n* Children (3≤ age \\\u003C18 years)\n* Includes women and minorities\n\nExclusion Criteria:\n\n• Subjects will be excluded if their condition makes them unable to continue with recordings.","3 Years","70 Years",{"count":239,"type":21},[143],"Overall, this study will investigate the functional utility of stereotyped HFOs by capturing them with a new implantable system (Brain Interchange - BIC of CorTec), which can sample neural data at higher rates \\>=1kHz and deliver targeted electrical stimulation to achieve seizure control. In contrast to current closed-loop systems (RNS), which wait for the seizure to start before delivering stimulation, the BIC system will monitor the spatial topography and rate of stereotyped HFOs and deliver targeted stimulation to these HFO generating areas to prevent seizures from occurring. If the outcomes of our research in an acute setting become successful, the investigators will execute a clinical trial and run the developed methods with the implantable BIC system in a chronic ambulatory setting.",[27],[254,255,27,256,257],"neuromodulation","HFO","Machine Learning","Closed-Loop",{"date":161,"type":38},{"date":260,"type":21},"2026-11-01",{"date":262,"type":21},"2029-08-31",{"name":264,"class":77},"Mayo Clinic",2,{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":46},"100582631","implementation-and-cost-evaluation-of-project-uplift-100582631","NCT06865820","Implementation and Cost Evaluation of Project UPLIFT","Inclusion Criteria:\n\n* Adults 18 years or older\n* Diagnosis of epilepsy (self-reported by patient)\n* Can speak English\n* Has access to a phone or computer\n\nExclusion Criteria:\n\n* Inability to cognitively participate",{"count":273,"type":21},60,[143],"This study tests Project Using Practice and Learning to Increase Favorable Thoughts (UPLIFT) which is a Mindfulness-based Cognitive Behavioral Therapy program teaching participants with epilepsy methods that include challenging thoughts, behavioral activation, coping, problem-solving, and mindfulness, for well-being and costs. Project UPLIFT is delivered as weekly sessions over 8 weeks.",[27],"2026-08-05",{"date":211,"type":38},{"date":280,"type":38},"2025-03-24",{"date":282,"type":21},"2027-08",{"name":76,"class":77},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":292,"targetDuration":294,"studyType":119,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":46},"100650767","domestication-and-implementation-of-the-pen-plus-clinical-model-in-the-zambian-health-system-100650767","NCT07753681","Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System","PEN-Plus Initiation Grant Opportunity: Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System","PEN Plus","Inclusion Criteria:\n\n* Presenting with chronic NCDs\n\nExclusion Criteria:\n\n* Refusing to be followed up prospectively for routine visits",{"count":293,"type":21},2084,"1 Month","Cognizant of the prevalence of complicated non communicable diseases (NCD) and the attendant capacity problems faced by the health workers in primary care settings, we propose to adapt and pilot the Package of Essential Non-communicable Diseases (PEN) Plus intervention using the Interactive Systems Framework (ISF) and then implement and monitor the impact. The ISF framework proposes and organizes several implementation strategies to achieve Evidence Based Implementation (EBI) adaptation. We will apply these strategies at 2 first level hospitals (Peri-Urban and Rural) to ensure local adaptation and work towards scaling up of the WHO-PEN Plus in the rest of Zambia. This process will be inclusive, involving a Stakeholder Consultation Group that shall include the Zambian Non-Communicable diseases and injuries (NCDI) Poverty Commission and shall report bi-annually to a Project Advisory Board (PAB) chaired by the Permanent Secretary of the Ministry of Health.",[297,298,299,300,301,302,303,27,304,305,306],"Cardiac Diseases","Sickle Cell Disease","Hypertension","Diabetes Mellitus","Heart Failure","Congenital Heart Disease","Rheumatic Heart Disease","Cancer","Mental Health Disorders","Kidney Disease","2026-08-04",{"date":211,"type":38},{"date":310,"type":38},"2022-08-08",{"date":312,"type":21},"2027-09-30",{"name":314,"class":77},"Centre for Infectious Disease Research in Zambia",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":83,"acronym":320,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":91,"conditions":324,"keywords":325,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":331},"100643647","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-100643647","NCT07594119","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 2",{"count":322,"type":21},312,[90],[93,27,94],[96,97],{"date":277,"type":38},{"date":328,"type":21},"2026-08",{"date":103,"type":21},{"name":105,"class":106},6,{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":356,"leadSponsor":358,"locationsCount":46},"100650695","phase-4-outcomes-after-planned-discontinuation-of-antiseizure-medication-100650695","NCT07750496","Outcomes After Planned Discontinuation of AntiSeizure Medication","Study Testing Outcomes After Planned Discontinuation of AntiSeizure Medication","STOP-ASM","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Diagnosis of epilepsy\n* At least 2 years since participants most recent seizure\n* At most 35% calculated 1-year post-discontinuation seizure risk, based upon the existing multivariable calculator if they are on only 1 ASM, otherwise no such restriction if they are more than 1 ASM\n* Willingness to adhere to the study intervention\n* Taking at least 1 antiseizure medication prior to enrollment\n\nExclusion Criteria:\n\n* Current pregnancy or planned pregnancy during the study period\n* History of epilepsy surgery\n* Large space-occupying radiographic lesion such as a large cortical tumor, large artery stroke, or encephalomalacia from traumatic brain injury.\n* Subject has any other clinically significant conditions or circumstances that in the judgment of the investigator or treating clinician should preclude study participation.\n\nPlease note: The researchers will ask participants not to drive for 2 months after ASM discontinuation if on monotherapy, and exercise caution while driving if stopping one antiseizure medication but remaining on others",{"count":20,"type":21},[342],"PHASE4","The main purpose of this study is to understand the effects of continuing versus discontinuing antiseizure medications after a period of seizure-freedom. Physician guidelines endorse that after a period of seizure-freedom, the risk of another seizure may be low enough to allow patients to consider coming off antiseizure medication to see if they still need it. However, evidence is limited regarding how much continuing antiseizure medication still reduces seizures versus increases side effects after a patient has been treated for a while. This study will determine whether discontinuing antiseizure medications benefits patients.",[27],[346,347,348,349,350,351],"Seizure","Antiseizure medications","Seizure Free","Feasibility","Acceptability","Discontinue medication","2026-08-02",{"date":354,"type":38},"2026-08-06",{"date":328,"type":21},{"date":357,"type":21},"2029-08",{"name":359,"class":77},"University of Michigan",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":16,"minAge":367,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":46},"100564040","bridging-the-treatment-gap-by-expanding-access-to-care-for-people-with-epilepsy-in-kenya-beacon-100564040","NCT06623994","Bridging the Treatment Gap by Expanding Access to Care for People With Epilepsy in Kenya (BEACON)","BEACON","Inclusion Criteria:\n\n* Individuals ≥12 years\n* Residents of Busia or Trans Nzoia County\n* Diagnosed with possible epilepsy through initial screening and confirmed diagnosis by an epilepsy-trained professional with the BEACON project or physician\n* Have a diagnosis of epilepsy but are not adherent to antiseizure medication treatment.\n\nExclusion Criteria:\n\n* Individuals receiving care from a neurosurgeon or neurologist for a serious brain disorder\n* Unable or unwilling to provide voluntary informed consent or assent (12-18 years)","12 Years",{"count":369,"type":21},650,[143],"This cluster randomized trial aims to learn about the effectiveness of task-sharing supported by an epilepsy medical records system (EMRS) (hereafter referred to as BEACON) with patient-tracking data in improving treatment adherence and retention in care in people with epilepsy in western Kenya.",[27],"2026-07-28",{"date":375,"type":38},"2026-07-29",{"date":377,"type":38},"2025-08-04",{"date":379,"type":21},"2028-10",{"name":381,"class":77},"University of Virginia",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":16,"minAge":225,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":391,"conditions":392,"keywords":395,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":46},"100649560","hobscotch-youth-and-young-adults-100649560","NCT07735715","HOBSCOTCH-YOUTH and Young Adults","Inclusion Criteria:\n\n* Inclusion Criteria for Young Adults with Epilepsy (YAWE) and Youth with Epilepsy (YWE):\n\n  * Age 18 - 29 years for YAWE\n  * Age 13 - 17 years for YWE\n  * For YWE at least one parent or legal guardian provides consent and agrees to participate\n  * Diagnosis of epilepsy (controlled or uncontrolled seizures)\n  * Subjective cognitive complaints (memory, attention, learning, problem solving, executive function, planning)\n  * Literate and proficient in English\n  * Telephone access\n  * Internet Access.\n\nInclusion Criteria for Parent of Youth with Epilepsy (YWE):\n\n* Parent or legal guardian of a youth with epilepsy (age 13 - 17 years)\n* Literate and proficient in English\n* Telephone access\n* Internet Access\n\nExclusion Criteria:\n\n* Active psychosis (any participant)\n* Illicit substance abuse (any participant)\n* Severe cognitive\u002Fintellectual disability (any participant)\n* YWE cannot participate without a parent and parent's consent (or legal guardian)\n* YWE cannot participate without assent even if a parent or legal guardian gives consent","29 Years",{"count":177,"type":21},[143],"The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 - 29 years, who have epilepsy. It will also learn if a modification of the program for youth with epilepsy, ages 13 - 17, improves thinking and memory and quality of life and reduces stress for their parents.\n\nResearchers will enroll 260 young adults with epilepsy and 40 youth with epilepsy and their parent or guardian. Researchers will compare responses to questionnaires and surveys before and after participation in the HOBSCOTCH program to see if thinking, memory and quality of life have improved for young adults and youth with epilepsy and to see if parents have improved quality of life as well.\n\nParticipants will:\n\n* Attend 9 weekly one-hour sessions of the HOBSCOTH program in their homes with a one-on-one coach using their computer or their phone; youth with epilepsy (ages 13 - 17) will attend alongside a parent or legal guardian.\n* Keep a short daily diary about their seizures and activity in the program using a smart phone app(lication)\n* Complete surveys and questionnaires before HOBSCOTCH and 3 months and 6 months later.\n\nThere are no study visits to a medical center. HOBSCOTCH is a virtual or telehealth intervention.",[27,393,394],"Cognitive Dysfunction, Cognitive Disorder","Memory and Thinking Problems",[27,32,393,396,397],"Memory and thinking problems","Epilepsy Self-Management","2026-07-24",{"date":400,"type":38},"2026-07-30",{"date":402,"type":21},"2026-09-01",{"date":404,"type":21},"2029-03-01",{"name":406,"class":77},"Dartmouth-Hitchcock Medical Center",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":430},"100636986","phase-1-a-phase-i-clinical-trial-of-ux-gip001-in-the-treatment-of-drug-resistant-unilateral-mesial-temporal-lobe-epilepsy-100636986","NCT07572812","A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of UX-GIP001 (Human GABAergic Interneuron Progenitor Cells Injection) in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy","Inclusion Criteria:\n\n* Age 18-75 years (inclusive), male or female;\n* Diagnosis of focal epilepsy according to the International League Against Epilepsy (ILAE) 2025 epilepsy classification, with disease duration ≥2 years;\n* Clinical presentation consistent with unilateral mesial temporal lobe epilepsy (MTLE);\n* Meeting the diagnostic criteria for drug-resistant epilepsy;\n* Average focal seizure frequency ≥4 per 28 days within the 3 months prior to screening;\n* On a stable dose of anti-seizure medications for ≥1 month prior to enrollment;\n* Patient has adequate organ function as follows: absolute neutrophil count ≥2.0×10⁹\u002FL; white blood cell count ≥4.0×10⁹\u002FL; platelet count ≥100×10⁹\u002FL; AST and ALT ≤2.5× upper limit of normal (ULN); total bilirubin ≤1.5× ULN; serum creatinine ≤1.5× ULN; estimated glomerular filtration rate (eGFR) ≥60 mL\u002Fmin\u002F1.73 m² (calculated using the CKD-EPI formula);\n* Women of childbearing potential must have a negative serum pregnancy test during the screening period. All participants and their partners agree to have no plans for pregnancy, sperm donation, or egg donation from the time of signing the informed consent form until 2 years after cell transplantation treatment, and voluntarily adopt contraceptive measures deemed effective by the investigator;\n* Patient has good compliance, with a patient diary completion rate ≥80% prior to enrollment.\n\nExclusion Criteria:\n\n* Epilepsy caused by other\u002For progressive neurological diseases , or patients - experiencing only focal aware seizures without observable manifestations.\n* History of epilepsy surgery.\n* History of status epilepticus within 12 months prior to screening.\n* Presence of long-term implants in the skull or intracranial space.\n* Severe systemic disease or dysfunction.\n* Primary or secondary immunodeficiency.\n* History of clear suicidal intent, plan, or behavior within one year prior to screening.\n* Severe psychiatric disorders.\n* History of malignancy within the past 5 years, except for cervical carcinoma in situ, basal cell or squamous cell skin cancer cured for \\>5 years.\n* Pregnant or breastfeeding women.",{"count":415,"type":21},12,[24],"This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE). The primary objective is to assess the safety, tolerability, and preliminary efficacy of UX-GIP001. This is an open-label, single-arm study. All enrolled participants will receive the active investigational cell therapy. Seizure frequency and safety parameters will be evaluated by comparing post-transplant outcomes to pre-transplant baselines.",[27],[27,420,421],"MTLE","Cell therapy",{"date":423,"type":38},"2026-07-27",{"date":425,"type":21},"2026-08-20",{"date":427,"type":21},"2029-07-01",{"name":429,"class":106},"Shanghai UniXell Biotechnology Co., Ltd",3,{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":46},"100526480","a-device-to-prevent-sudden-unexpected-death-in-epilepsy-detecting-peri-ictal-body-position-100526480","NCT06135285","A Device to Prevent Sudden Unexpected Death in Epilepsy: Detecting Peri-Ictal Body Position","Inclusion criteria:\n\n1\\. Adults 18 years of age or older admitted to the BWH EMU with drug-resistant epilepsy, defined by the failure of at least two anti-seizure medications and a documented history of electroclinical seizures\n\nExclusion criteria:\n\n1. Suspicion of functional dissociative seizures (psychogenic nonepileptic seizures)\n2. Patients admitted for medication adjustment only",{"count":141,"type":21},[143],"The goal of this study is to assess the performance of a commercial sheet sensor in determining body position after generalized tonic-clonic (GTC) seizures. If a sheet sensor could accurately detect GTC seizures, this could be a step towards autonomously repositioning patients with the aid of a smart mattress.\n\nPrimary Objective\n\nMilestones:\n\nFeasibility objective: Monitor 50 patients with the objective of capturing at least 20 GTCS events. Primary analytic objective: Achieve detection of anatomical landmarks with body position change within 5 seconds with an accuracy of 75% both interictally and post-GTCS.\n\nSecondary Objective Detect the postictal prone position with an accuracy of 100%.",[27],{"date":423,"type":38},{"date":443,"type":21},"2026-08-15",{"date":445,"type":21},"2027-06",{"name":447,"class":77},"Brigham and Women's Hospital",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":16,"minAge":294,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":471},"100417435","phase-3-a-study-to-test-the-safety-and-tolerability-of-brivaracetam-in-children-and-adolescents-with-seizures-100417435","NCT04715646","A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures","Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy","Inclusion Criteria:\n\nInclusion criteria for long-term follow-up (LTFU) study participants only\n\n* Study participants ≥ 1 month of age with a confirmed diagnosis of epilepsy who participated in core study N01266 \\[NCT01364597\\] and\u002For N01349 \\[NCT03325439\\]\n\nInclusion criteria for directly enrolled (DE) study participants in Japan only\n\n* Study participant is ≥ 4 years to \\\u003C 16 years of age\n* Study participant has presence of an electroencephalogram (EEG) reading compatible with the diagnosis of focal epilepsy within the last 10 years\n* Study participant has uncontrolled partial-onset seizure (POS) after an adequate course of treatment with at least 1 antiepileptic drug (AED)\n* Study participant had at least 1 POS during the 4-week Screening Period\n\nExclusion Criteria:\n\nExclusion criteria for all study participants\n\n* Severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the study participant\n* Study participant is currently participating in another study of an investigational medication (or a medical device) other than brivaracetam (BRV).\n\nExclusion criteria for long-term follow-up (LTFU) study participants only\n\n\\- Study participant ≥ 6 years of age has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS)\n\nExclusion criteria for directly enrolled (DE) study participants in Japan only\n\n* Study participant has a history of primary generalized epilepsy, psychogenic non-epileptic seizures, or febrile seizures\n* Study participant has a history of status epilepticus in the 30 days prior to the Screening Visit (ScrV) or during the Screening Period\n* Study participant has any clinically significant illness\n* Study participant has clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results\n* Study participant has a clinically significant ECG abnormality\n* Study participant had major surgery within 6 months prior to the ScrV",{"count":456,"type":21},70,[90],"The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.",[27],[27,461,462,463],"Brivaracetam","Pediatric","Child",{"date":423,"type":38},{"date":466,"type":38},"2021-03-11",{"date":468,"type":21},"2030-07-08",{"name":470,"class":106},"UCB Biopharma SRL",36,{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":46},"100632997","lilys-grace-temporal-interference-100632997","NCT07520955","Lily's Grace Temporal Interference","Using Temporal Interference to Non-Invasively Enhance Sleep Homeostasis in Patients With Epilepsy","SLEEP-TIES","Inclusion Criteria:\n\n* English-speaking (able to provide consent and complete questionnaires)\n* Citizen or holding permanent resident status\n* History of refractory epilepsy with intractable seizures and\u002For cognitive decline\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease other than epilepsy (e.g. stroke, traumatic brain injury), including intracranial lesions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* Possible pregnancy or plan to become pregnant in the next 6 months\n* Any metal in the head\n* Any metal in the body\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator) unless otherwise approved by the responsible MD\n* Dental implants\n* Permanent retainers\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for several hours\n* Regular night-shift work (second or third shift)",{"count":481,"type":21},24,[143],"This study is to evaluate the effectiveness of targeted Transcranial Electrical Stimulation with Temporal Interference (TES-TI) interventions to boost Non-Rapid Eye Movement (NREM) sleep, decrease seizures and promote emotional health in patients with epilepsy. Up to 24 participants (8 control participants for technical optimization prior to recruitment and 16 patients with epilepsy) will be enrolled and can expect to be on study for up to 24 months.",[27],[486,487],"seizures","non rapid eye movement sleep","2026-07-22",{"date":490,"type":38},"2026-07-23",{"date":328,"type":21},{"date":493,"type":21},"2028-04",{"name":495,"class":77},"University of Wisconsin, Madison",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":502,"enrollmentInfo":503,"targetDuration":504,"studyType":119,"phases":4,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":46},"100604268","multimodal-pet-imaging-with-18f-fdgsv2atspo-for-resection-planning-in-drug-resistant-epilepsy-100604268","NCT07147309","Multimodal PET Imaging With 18F-FDG\u002FSV2A\u002FTSPO for Resection Planning in Drug-Resistant Epilepsy","Inclusion Criteria:\n\n* with drug-resistant focal epilepsy defined by ILAE criteria\n* Already performed 3.0 T epilepsy-protocol MRI and video-EEG\n* Planned resective surgery or stereotactic EEG (SEEG) electrode implantation, and willingness to undergo all three PET scans: ¹⁸F-FDG, SV2A, and TSPO.\n* Ability to understand study procedures and provide written informed consent.\n* Availability of complete postoperative follow-up data with at least 12-month Engel outcome classification.\n\nExclusion Criteria:\n\n-History of head trauma ,claustrophobia, rheumatic or autoimmune diseases, psychiatric disorders, severe somatic diseases (neurological,cardiovascular, etc.),previous heart or brain surgery, substance abuse, inability to refrain from hypnotics, magnetic implants, pregnancy, lactation","50 Years",{"count":273,"type":21},"2 Years","This study focuses on the application value of 18F-FDG, SV2A, and TSPO PET imaging in the preoperative localization of epileptogenic foci in epilepsy. 18F-FDG PET detects glucose metabolism in brain tissue and is characterized by reduced metabolism during the interictal period. It is currently the most commonly used localization method in clinical practice, especially suitable for temporal lobe epilepsy, but has limited sensitivity to foci with insignificant metabolic changes. SV2A PET targets synaptic vesicle proteins and reflects synaptic density, showing reduced uptake in epileptogenic foci areas. It has high localization accuracy, can effectively supplement the diagnosis of 18F-FDG PET-negative cases, and also has good application prospects in non-temporal lobe epilepsy. TSPO PET monitors microglial activation to reflect neuroinflammation, with increased uptake in epileptogenic foci areas, and has unique auxiliary diagnostic value in refractory epilepsy and cases with concurrent brain injury. The combined application of the three can provide a more comprehensive imaging basis for preoperative localization of epilepsy, helping to optimize surgical plans.",[27,507,508,509,510],"PET \u002F MR","Synaptic Vesicle Proteins","Microglial Activation","FDG PET","2026-07-20",{"date":513,"type":38},"2026-07-21",{"date":515,"type":38},"2025-09-01",{"date":517,"type":21},"2029-09-01",{"name":519,"class":77},"Weibing Miao, PhD",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":16,"minAge":528,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":46},"100402884","real-world-evidence-in-patient-reported-outcomes-for-medical-cannabis-mc-rwe-100402884","NCT04526093","Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)","MC-RWE : Real World Evidence in Patient-Reported Outcomes for Medical Cannabis: A Prospective Observational Study","MC-RWE","Inclusion Criteria:\n\n* Subjects (≥19 years of age) who are MC-naïve or -experienced with a medical authorization for MC provided by a prescribing health care practitioner and who have provided informed consent\n* Primary therapeutic indications for MC use: pain, epilepsy, sleep, and\u002For anxiety\u002Fdepression.\n* Subjects agree to use verified products and refrain from using any other cannabis products, either medical or recreational, during the duration of the study\n\nExclusion Criteria:\n\n* Concomitant use of illicit drugs\n* Concomitant use of recreational cannabis","19 Years",{"count":530,"type":21},1000,"This prospective observational study aims to describe the effectiveness of MC on pain, epilepsy, sleep and \u002For anxiety\u002Fdepression in a cohorts of patients authorized to use MC, using pre-defined, validated self assessment scales.",[533,534,535,63,27],"Pain","Sleep","Anxiety",{"date":488,"type":38},{"date":538,"type":38},"2020-07-15",{"date":540,"type":21},"2028-07",{"name":168,"class":77},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":248,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":551,"briefSummary":553,"conditions":554,"keywords":561,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":46},"100648608","early-phase-1-human-cognition-during-surgery-stimulation-based-and-cholinergic-modulation-100648608","NCT07721272","Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation","Studying Human Cognition During Deep Brain Stimulation Surgery Using High-Density Neural Probes and Pharmacological Interventions","Study Population\n\nInclusion Criteria for Essential Tremor Patients:\n\n* Diagnosis of Essential Tremor\n* Recommended to undergo deep brain stimulation implantation surgery for surgical management of medication-resistant tremor based on clinical indications\n\nExclusion Criteria for Essential Tremor Patients:\n\n* Patients with recent use (within one week) of anticoagulant or antiplatelet agent\n* Contraindication to use of cholinergic modulation\n\nInclusion Criteria for Epilepsy Patients\n\n* Diagnosis of intractable epilepsy\n* Undergoing neuromodulation procedure that utilizes insertion of electrodes into subcortical structures, including the thalamus or hippocampus\n* Undergoing neuromodulation procedure that utilizes frame-based insertion of electrodes into the thalamus (ANT or CM)\n\nExclusion Criteria for Epilepsy Patients:\n\n* Patients with recent use (within one week) of anticoagulant or antiplatelet agent\n* Contraindication to use of cholinergic modulation\n\nContraindication for cholinergic modulation in both patient sets will be assessed by members of the treatment team (e.g. epileptologist), as well as a neuroanesthesiologist. Multiple medications and conditions are singular disqualifiers; however some medications are eliminated only in combination following neuroanesthesiologist evaluation. Patients at risk of reaction to the treatment arm based on concurrent or recent medications or other health conditions will be excluded from participation.\n\nInclusion Criteria for Study Participation\n\n* Is patient between 18-70?\n* In general good health, aside from history of epilepsy or essential tremor, as ascertained by medical history, physical exam, clinical labs, and ECG?\n* Candidate for surgery as determined independently by the patient's treating physician\u002Fclinical team as part of the patient's routine medical care?\n* Able to read, understand, and provide written, dated informed consent, and participate in cognitive tasks?\n\nExclusion Criteria for Study Participation\n\n* Female that is pregnant, breastfeeding, or has a positive pregnancy test?\n* Under 18, over 70, or currently a prisoner on medical release?\n* Hepatic impairment (moderate or severe)?\n* Renal impairment (moderate or severe)?\n* Untreated narrow angle glaucoma?\n* Bladder obstruction, prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention?\n* History of hypersensitivity to COBENFY or trospium chloride?\n* Biliary disease, including symptomatic gallstones, gallbladder disorders, pancreatitis?\n* Fluoxetine, paroxetine, bupropion, terbinafine?\n* Buspirone or eletriptan?\n* Digoxin, colchicine, apixaban?\n* Diphenhydramine, beztropine, oxybutynin?\n* Benztropine, trihexyphenidyl, tolterodine, solifenacin, darifenacin, fesoterodine, hyoscyamine, dicyclomine, scopolamine?",{"count":550,"type":21},30,[552],"EARLY_PHASE1","This is a research study to determine how COBENFY KarXT (FDA approved), a drug which has been approved for treatment of certain disorders, affects brain activity and cognitive tasks which may be regulated by the cholinergic system.\n\nThis study aims to answer: 1) how cholinergic circuitries act during task performance in humans, and 2) develop a better understanding of how cognitive control interacts with learning, memory and decision making in the setting of cholinergic manipulation.\n\nParticipants will complete a single treatment arm, regardless of which surgical procedure they are to receive. An anesthesiologist or other clinical staff will administer either the drug or the saline at a critical point which addresses the research questions, prior to patient surgery. This will be either with the drug, or the placebo pill. Half of the participants will be randomized to receive the drug, and the other half of these the placebo. Participants will be unaware whether the actual drug has been received.\n\nEssential tremor patients who participate will complete a cognitive task during an awake surgery. Epilepsy patients who participate will have a resting state recording during the procedure from the deep cortical layers of the brain. A probe will be used during the surgery to measure the effects of this drug and other procedures of the study on the cholinergic system. This probe is the clinical probe known as the AlphaOmega, which is FDA approved for standard of care procedures.\n\nResearchers will compare the brain activity between treatment arms to determine what brain activity changes based on the cholinergic manipulation.",[27,147,32,555,556,557,558,559,560],"Memory Consolidation","Memory Disorders","Memory Replay","Memory Encoding","Cognitive Control","Motor Abilities",[562,563,564,565,566,567,568],"interoperative","oscillatory changes","neuronal spiking","time cell","place cell","cholinergic agonist","cholinergic modulation","2026-07-17",{"date":490,"type":38},{"date":572,"type":21},"2026-10",{"date":574,"type":21},"2030-09",{"name":576,"class":77},"University of Texas Southwestern Medical Center",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":16,"minAge":367,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":4},"100449443","neural-basis-of-cognition-100449443","NCT05132543","Neural Basis of Cognition","Studying Human Cognition and Neurological Disorders Using µECoG Electrodes","Inclusion Criteria:\n\n* Potential subjects will come from adult and pediatric patients (between the ages of 12 and 18) undergoing surgery for the treatment of pharmacologically resistant epilepsy, brain tumor resection, brain mass resection, or deep brain stimulation (DBS) for the first time\n* Proficient English speakers\n* No Major cognitive impairment\n\nExclusion Criteria:\n\n* Previous DBS procedure\n* Subject unable to consent to study",{"count":585,"type":21},38,[143],"The overall purpose of this study is to better understand human cognition and human epilepsy by working with patients undergoing clinical treatment for pharmacologically resistant epilepsy. The investigators will investigate human cognition by conducting controlled experiments that focus on sensory, motor, and cognitive phenomena such as sensory processing, memory, and language. The investigators will also examine the neural underpinnings of epilepsy during both sleep and wakefulness to better understand both the foundations of epilepsy and how epilepsy affects cognition. The investigators hope to use these data to have a better understanding of cognition, epilepsy, and how the two interact. This will potentially lead to better markers for seizure onsets as well as epilepsy more generally. For this research, the investigators will use μECoG arrays manufactured by commercial partners. These arrays have passed all major ISO 10993 bio-compatibility tests. Based on this characterization and use in the intraoperative setting (limited duration and supervised usage), these devices pose a minimal risk to participants. Data will be analyzed and protected using the Duke SSRI protected research data network.",[27],"2026-07-16",{"date":569,"type":38},{"date":592,"type":21},"2026-09",{"date":594,"type":21},"2027-09-15",{"name":596,"class":77},"Duke University",{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":605,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":607,"conditions":608,"keywords":610,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":622},"100601435","diagnosing-epilepsy-to-effect-change-long-term-follow-up-100601435","NCT07110454","Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up","A Prospective Long-Term Follow-Up Study to Evaluate the Use of the Minder Device to Aid in Treatment After Actionable Event Identification in Patients Diagnosed With Epilepsy.","DETECT LTFU","Inclusion Criteria:\n\n* Participant met all inclusion criteria, was enrolled in the DETECT study, and received the Minder device\n* Participant completed the DETECT study by receiving an actionable event or by completing the 6-month follow-up visit\n* Participant continues to have the Minder device implanted\n* Participant must continue to meet relevant DETECT study inclusion criteria\n\nExclusion Criteria:\n\n* Participant meets any relevant DETECT study exclusion criteria including needing treatments or assessments that are not indicated with the Minder System like Magnetic Resonance Imaging (MRI)",{"count":606,"type":21},210,"The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational.\n\nParticipants that have completed the DETECT study and received the Minder System previously will consent to join this long-term follow-up observational study. The study will collect information about general wellbeing, use of healthcare services, and experience using the Minder data over time to support long-term epilepsy care.\n\nAll participants will continue to be followed by their treating physician and undergo assessments and visits every six (6) months until two (2) years after receiving the Minder device.",[27,609],"Epilepsy (Treatment Refractory)",[611,612],"Minder System","Sub-scalp EEG monitoring device","2026-07-14",{"date":615,"type":38},"2026-07-15",{"date":617,"type":21},"2026-06",{"date":619,"type":21},"2029-01",{"name":621,"class":106},"Epiminder America, Inc.",16,{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":631,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":635,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":640,"locationsCount":641},"100601426","diagnosing-epilepsy-to-effect-change-100601426","NCT07110337","Diagnosing Epilepsy To EffeCT Change","A Prospective Study to Evaluate the Use of the Minder Device to Aid in Developing a Treatment Plan After Inconclusive Prolonged EEG in Patients With Epilepsy","DETECT","Inclusion Criteria:\n\n* Diagnosis of focal and\u002For generalized epilepsy.\n* Drug-resistant\n* At least an average of 1 seizure within the past 3 months\n* Participant completed a multi-day EEG assessment that was inconclusive, and is unchanged since the last EEG monitoring.\n\nExclusion Criteria:\n\n* Epilepsy surgery within the past 6 months\n* Active Deep Brain Stimulation (DBS) or Responsive Neurostimulator System (RNS)\n* Participant needs treatments or assessments that are not indicated with the Minder System like Magnetic Resonance Imaging (MRI), Electro-Convulsive Therapy (ECT), lithrotripsy, and diathermy\n* Participant cannot have surgery to have the device implanted",{"count":606,"type":21},[143],"The purpose of this research is to address the challenges of diagnosing and long-term management of epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research will compare the Minder System to standard of care in providing reliable seizure data. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational.\n\nParticipants will consent to join the study and be implanted with the Minder device; or consent to join the study and continue with their Standard of Care (SOC) as a control group. Participants chose to be implanted with the Minder device will have the device implanted under their scalp. After implantation, participants will be randomly assigned to a group where their treating physician will have access to the EEG data collected by the Minder System or a group where their treating physician does not have access to the EEG data collected by the Minder System. Participants receiving the Minder System will not know which group they are in (blinded) until the study ends.\n\nAll participants will continue to be followed by their treating physician and undergo assessments and visits until enough information is available to determine a treatment plan or the 6-month follow-up visit.",[27,609],[611,612],{"date":615,"type":38},{"date":638,"type":38},"2025-12-23",{"date":445,"type":21},{"name":621,"class":106},19]